Triple

T9807086
Position Surface form Disambiguated ID Type / Status
Subject MabThera E238179 entity
Predicate hasEquivalentProduct P7398 FINISHED
Object Rituxan E46089 NE FINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Rituxan | Statement: [MabThera, hasEquivalentProduct, Rituxan]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Rituxan
Context triple: [MabThera, hasEquivalentProduct, Rituxan]
  • A. Rituxan chosen
    Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • B. Humira
    Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
  • C. Imbruvica
    Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • D. Remicade
    Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
  • E. Stelara
    Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
PD Predicate disambiguation gpt-5-mini-2025-08-07
Target predicate: hasEquivalentProduct
Context triple: [MabThera, hasEquivalentProduct, Rituxan]
  • A. hasProduct
    Indicates that an entity possesses, offers, or is associated with a particular product.
  • B. hasEquivalent chosen
    Indicates that two entities are considered equal in value, meaning, or function within a given context.
  • C. isAlternativeTo
    Indicates that one entity can serve as a substitute or different option in place of another.
  • D. equivalentIn
    Indicates that two entities are considered logically or functionally the same in meaning, status, or effect within a given context.
  • E. materiallySimilarTo
    Indicates that two entities share substantially the same physical or material characteristics, composition, or properties, though they may not be exactly identical.
  • F. None of above.

Provenance (4 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69ca84defac48190abc1148804f184c1 completed March 30, 2026, 2:12 p.m.
NER Named-entity recognition batch_69cdab7cb9588190953a063cb7b9e29e completed April 1, 2026, 11:34 p.m.
NED1 Entity disambiguation (via context triple) batch_69d1d5aecdec81909fae349945406c6c completed April 5, 2026, 3:23 a.m.
PD Predicate disambiguation batch_69cd03dd2da881909052fbf29736a773 completed April 1, 2026, 11:39 a.m.
Created at: March 30, 2026, 8:29 p.m.